CAMZYOS (mavacamten)
CARDIAC MYOSIN MODULATORS (INHIBITORS AND ACTIVATORS) · HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY
MYOKARDIA, INC.
Drug class
Cardiac Myosin Modulators (Inhibitors and activators)
Cardiac myosin modulators constitute a class of targeted small-molecule agents that directly interact with cardiac sarcomeric beta-myosin to regulate myocardial contractility without altering intracellular calcium handling. Read more about Cardiac Myosin Modulators (Inhibitors and activators)
2 drugs in this class 2 manufacturers
Drugs in Cardiac Myosin Modulators (Inhibitors and activators)
MYQORZO (aficamten)
CARDIAC MYOSIN MODULATORS (INHIBITORS AND ACTIVATORS) · HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY
CYTOKINETICS, I
Filter & compare in the drug finder →
Opens the drug finder with Cardiac Myosin Modulators (Inhibitors and activators) preselected. Add indication or manufacturer filters there.
Cardiac myosin modulators constitute a class of targeted small-molecule agents that directly interact with cardiac sarcomeric beta-myosin to regulate myocardial contractility without altering intracellular calcium handling.
Within this class, cardiac myosin inhibitors decrease the formation of actin-myosin cross-bridges to relieve pathological hypercontractility, reducing left ventricular outflow tract gradients in conditions such as obstructive hypertrophic cardiomyopathy.
Conversely, cardiac myosin activators promote cross-bridge recruitment to prolong systolic ejection and enhance contractile efficiency, an approach developed primarily to improve cardiac performance in heart failure with reduced ejection fraction.
Together, these agents provide mechanism-targeted pharmacotherapy across the spectrum of myocardial contractile disorders.
-
bocsci.com
Cardiac myosin modulators constitute a class of targeted small-molecule agents that directly interact with cardiac sarcomeric beta-myosin to regulate myocardial contractility without altering intracellular calcium handling
-
nih.gov
Cardiac myosin modulators constitute a class of targeted small-molecule agents that directly interact with cardiac sarcomeric beta-myosin to regulate myocardial contractility without altering intracellular calcium handling Conversely, cardiac myosin activators promote cross-bridge recruitment to prolong systolic ejection and enhance contractile efficiency, an approach developed primarily to improve cardiac performance in heart failure with reduced ejection fraction Together, these agents provide...
-
fda.gov
Within this class, cardiac myosin inhibitors decrease the formation of actin-myosin cross-bridges to relieve pathological hypercontractility, reducing left ventricular outflow tract gradients in conditions such as obstructive hypertrophic cardiomyopathy
-
4hcm.org
Within this class, cardiac myosin inhibitors decrease the formation of actin-myosin cross-bridges to relieve pathological hypercontractility, reducing left ventricular outflow tract gradients in conditions such as obstructive hypertrophic cardiomyopathy
-
patsnap.com
Conversely, cardiac myosin activators promote cross-bridge recruitment to prolong systolic ejection and enhance contractile efficiency, an approach developed primarily to improve cardiac performance in heart failure with reduced ejection fraction
-
nih.gov
Conversely, cardiac myosin activators promote cross-bridge recruitment to prolong systolic ejection and enhance contractile efficiency, an approach developed primarily to improve cardiac performance in heart failure with reduced ejection fraction
-
youtube.com
Together, these agents provide mechanism-targeted pharmacotherapy across the spectrum of myocardial contractile disorders
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.